The advantages of shingles vaccines appear to keep expanding.
As noted earlier, this vaccine not only helps guard against the painful rashes associated with the virus, but it also might lower the risk of developing dementia.
Recently, a study suggested that shingles vaccines could also reduce heart disease risk for as long as eight years.
Exploring Common Vaccine Benefits
In a comprehensive long-term study involving over 1.2 million people aged 50 and older in South Korea, researchers explored vaccination rates and their links to various cardiovascular conditions over a period of 12 years.
Those who had received the shingles vaccine were found to have a 23% reduced risk of heart-related issues, such as stroke, heart failure, and coronary artery disease.
Interestingly, the benefits seemed to be more significant in individuals under 60, which might suggest a more robust immune response in that age group.
Unexpected Connections with Blood Pressure and Dementia
The vaccine’s positive effects on heart health were especially noticeable among men and those with unhealthy habits, like being sedentary, drinking, or smoking.
This research was published in the European Journal of Hearts on Tuesday.
Shingles symptoms can lead to severe complications, particularly for older adults and those with compromised immune systems. Without vaccination, statistics show that around 30% of individuals will experience shingles sometime in their lives.
“In addition to the rash, iron fragments are linked to a heightened risk of heart issues, so I was curious if vaccination could help mitigate that risk,” a researcher remarked in a press release.
“Our research indicates that shingles vaccines may contribute to a reduced risk of heart disease, even among those without typical risk factors.”
This suggests that the benefits of vaccination might extend beyond simply preventing shingles.
Researchers pointed out a few possible mechanisms explaining these heart health benefits. “A shingles infection can lead to vascular damage and inflammation, increasing the likelihood of heart disease,” one researcher explained. “By preventing shingles, vaccinations may help lower these risks.”
Potential Limitations
Dr. Jasdeep Dalawari, a cardiologist who wasn’t part of the study, emphasized the need for careful evaluation of the findings, especially in relation to the U.S. population.
“The findings are indeed significant, but they must be interpreted with caution,” he mentioned.
He brought up an important point: “We used live vaccines for this research, while in the U.S., Singlix, a non-live recombinant vaccine, is primarily used.” He noted that Singlix shows efficacy over 90% against shingles, compared to just 51% for live vaccines.
Cardiologists have highlighted the distinction between correlation and causation in observational studies, indicating that further investigations are necessary.
Dr. Dalawari added, “The study focused on one ethnic group of individuals over 50. Including a broader range of ethnic backgrounds would enhance the findings, particularly in our diverse society.”
While the study accounted for various health conditions and lifestyle factors, the researchers acknowledged certain limitations. “Since this research examined an Asian cohort, the implications may not translate universally,” one researcher pointed out. “Although we conducted a thorough analysis, this doesn’t establish a definite cause-and-effect relationship, so potential biases from other factors should be contemplated.”
The research team has plans to look deeper into the heart health advantages offered by non-live recombinant vaccines containing viral proteins.
